Exagen Analyst Ratings
Exagen Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 11/17/2022 | 105.88% | BTIG | $10 → $7 | Maintains | Buy |
| 11/15/2022 | 105.88% | Canaccord Genuity | $8 → $7 | Maintains | Buy |
| 05/13/2022 | 400% | Keybanc | $20 → $17 | Maintains | Overweight |
| 03/25/2022 | 488.24% | Keybanc | $30 → $20 | Maintains | Overweight |
| 11/11/2021 | 782.35% | Keybanc | $33 → $30 | Maintains | Overweight |
| 04/15/2021 | 635.29% | Canaccord Genuity | → $25 | Initiates Coverage On | → Buy |
| 03/02/2021 | 870.59% | Keybanc | $32 → $33 | Maintains | Overweight |
| 11/10/2020 | 841.18% | Keybanc | → $32 | Initiates Coverage On | → Overweight |
| 10/08/2020 | 429.41% | BTIG | → $18 | Initiates Coverage On | → Buy |
| 06/02/2020 | 488.24% | Cantor Fitzgerald | $19 → $20 | Assumes | → Overweight |
| 11/13/2019 | 635.29% | Cantor Fitzgerald | $18 → $25 | Maintains | Overweight |
| 10/14/2019 | 429.41% | Cantor Fitzgerald | → $18 | Initiates Coverage On | → Overweight |
| 10/14/2019 | 400% | Cowen & Co. | → $17 | Initiates Coverage On | → Outperform |
| 10/14/2019 | — | William Blair | Initiates Coverage On | → Outperform |
| 日期 | 上行/下行 | 分析公司 | 目標價格變化 | 評級變化 | 上一次/當前評級 |
|---|---|---|---|---|---|
| 11/17/2022 | 105.88% | BTIG | $10 → $7 | 維護 | 買 |
| 11/15/2022 | 105.88% | 卡納科特·格納奇 | $8 → $7 | 維護 | 買 |
| 05/13/2022 | 400% | KeyBanc | $20 → $17 | 維護 | 超重 |
| 03/25/2022 | 488.24% | KeyBanc | $30 → $20 | 維護 | 超重 |
| 11/11/2021 | 782.35% | KeyBanc | $33 → $30 | 維護 | 超重 |
| 04/15/2021 | 635.29% | 卡納科特·格納奇 | → $25 | 開始承保 | →購買 |
| 03/02/2021 | 870.59% | KeyBanc | $32 → $33 | 維護 | 超重 |
| 11/10/2020 | 841.18% | KeyBanc | → $32 | 開始承保 | →超重 |
| 10/08/2020 | 429.41% | BTIG | → $18 | 開始承保 | →購買 |
| 06/02/2020 | 488.24% | 康託·菲茨傑拉德 | $19 → $20 | 假設 | →超重 |
| 11/13/2019 | 635.29% | 康託·菲茨傑拉德 | $18 → $25 | 維護 | 超重 |
| 10/14/2019 | 429.41% | 康託·菲茨傑拉德 | → $18 | 開始承保 | →超重 |
| 10/14/2019 | 400% | 考恩公司 | → $17 | 開始承保 | →跑贏大盤 |
| 10/14/2019 | — | 威廉·布萊爾 | 開始承保 | →跑贏大盤 |
What is the target price for Exagen (XGN)?
埃克森美孚的目標價是多少？
The latest price target for Exagen (NASDAQ: XGN) was reported by BTIG on November 17, 2022. The analyst firm set a price target for $7.00 expecting XGN to rise to within 12 months (a possible 105.88% upside). 4 analyst firms have reported ratings in the last year.
北京國際集團於2022年11月17日報道了埃克森美孚(納斯達克：XGN)的最新目標價。這家分析公司將XGN的目標價設定為7美元，預計XGN將在12個月內上漲至(可能上漲105.88%)。去年有4家分析公司公佈了評級。
What is the most recent analyst rating for Exagen (XGN)?
分析師對埃克森美孚的最新評級是多少？
The latest analyst rating for Exagen (NASDAQ: XGN) was provided by BTIG, and Exagen maintained their buy rating.
納斯達克(Sequoia Capital：XGN)的最新分析師評級由北京國際集團提供，艾克森維持買入評級。
When is the next analyst rating going to be posted or updated for Exagen (XGN)?
Exagen(XGN)的下一次分析師評級將於何時發佈或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Exagen, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Exagen was filed on November 17, 2022 so you should expect the next rating to be made available sometime around November 17, 2023.
分析師在進行了廣泛的研究後得出了股票評級，其中包括查閲公共財務報表，與Exagen的高管和客户交談，以及收聽收益電話會議。大多數分析師每三個月就會這樣做一次，所以你每年應該會得到每家公司每家公司的4個評級。Exagen的上一次評級是在2022年11月17日提交的，所以你應該預計下一次評級將在2023年11月17日左右提供。
Is the Analyst Rating Exagen (XGN) correct?
分析師評級Exagen(XGN)正確嗎？
While ratings are subjective and will change, the latest Exagen (XGN) rating was a maintained with a price target of $10.00 to $7.00. The current price Exagen (XGN) is trading at is $3.40, which is out of the analyst's predicted range.
雖然評級是主觀的，並將發生變化，但最新的Exagen(XGN)評級維持不變，目標價在10.00美元至7.00美元之間。埃克森美孚目前的交易價格為3.40美元，超出了分析師的預測區間。
譯文內容由第三人軟體翻譯。